A

Affimed NV
D

AFMD

2.85000
USD
-0.10
(-3.39%)
Market Closed
Volume
0
EPS
-4
Div Yield
-
P/E
-1
Market Cap
46,718,178
Related Instruments
    A
    ADAP
    -0.00320
    (-0.54%)
    0.58680 USD
    A
    ARVN
    -2.440
    (-9.78%)
    22.500 USD
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    G
    GTHX
    0.01000
    (0.14%)
    7.16000 USD
    N
    NTLA
    -1.165
    (-7.71%)
    13.955 USD
    R
    RCKT
    -0.810
    (-5.48%)
    13.980 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    V
    VYGR
    -0.57000
    (-9.18%)
    5.64000 USD
    More
News

Title: Affimed NV

Sector: Healthcare
Industry: Biotechnology
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents anapproach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.